|
1
|
Zhu YH, Fu L, Chen L, Qin YR, Liu H, Xie
F, Zeng T, Dong SS, Li J, Li Y, et al: Downregulation of the novel
tumor suppressor DIRAS1 predicts poor prognosis in esophageal
squamous cell carcinoma. Cancer Res. 73:2298–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Offner FA: Etiology, molecular biology and
pathology of squamous cell carcinoma of the esophagus. Pathologe.
21:349–357. 2000.In German. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kong KL, Kwong DL, Fu L, Chan TH, Chen L,
Liu H, Li Y, Zhu YH, Bi J, Qin YR, et al: Characterization of a
candidate tumor suppressor gene uroplakin 1A in esophageal squamous
cell carcinoma. Cancer Res. 70:8832–8841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H,
Li H, Shu XS, Li H, Liu W, et al: CMTM3, located at the critical
tumor suppressor locus 16q22.1, is silenced by CpG methylation in
carcinomas and inhibits tumor cell growth through inducing
apoptosis. Cancer Res. 69:5194–5201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi Y, Iwai M, Kawai T, Arakawa A,
Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, et al:
Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive
lesions of primary breast cancer. Breast Cancer. 19:242–252. 2012.
View Article : Google Scholar
|
|
9
|
Yamada D, Kikuchi S, Williams YN,
Sakurai-Yageta M, Masuda M, Maruyama T, Tomita K, Gutmann DH,
Kakizoe T, Kitamura T, et al: Promoter hypermethylation of the
potential tumor suppressor DAL-1/4.1B gene in renal clear cell
carcinoma. Int J Cancer. 118:916–923. 2006. View Article : Google Scholar
|
|
10
|
Jiang W and Newsham IF: The tumor
suppressor DAL-1/4.1B and protein methylation cooperate in inducing
apoptosis in MCF-7 breast cancer cells. Mol Cancer. 5:42006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z, Zhang J, Ye M, Zhu M, Zhang B, Roy
M, Liu J and An X: Tumor suppressor role of protein 4.1B/DAL-1.
Cell Mol Life Sci. 71:4815–4830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li X, Zhou F, Jiang C, Wang Y, Lu Y, Yang
F, Wang N, Yang H, Zheng Y and Zhang J: Identification of a DNA
methylome profile of esophageal squamous cell carcinoma and
potential plasma epigenetic biomarkers for early diagnosis. PLoS
One. 9:e1031622014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng R, Huang JP, Li XF, Xiong WB, Wu G,
Jiang ZJ, Song SJ, Li JQ, Zheng YF and Zhang JR: Epb41l3 suppresses
esophageal squamous cell carcinoma invasion and inhibits MMP2 and
MMP9 expression. Cell Biochem Funct. 34:133–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saeki T, Mhashilkar A, Swanson X, Zou-Yang
XH, Sieger K, Kawabe S, Branch CD, Zumstein L, Meyn RE, Roth JA, et
al: Inhibition of human lung cancer growth following
adenovirus-mediated mda-7 gene expression in vivo. Oncogene.
21:4558–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ji L, Fang B, Yen N, Fong K, Minna JD and
Roth JA: Induction of apoptosis and inhibition of tumorigenicity
and tumor growth by adenovirus vector-mediated fragile histidine
triad (FHIT) gene overexpression. Cancer Res. 59:3333–3339.
1999.PubMed/NCBI
|
|
16
|
Roz L, Gramegna M, Ishii H, Croce CM and
Sozzi G: Restoration of fragile histidine triad (FHIT) expression
induces apoptosis and suppresses tumorigenicity in lung and
cervical cancer cell lines. Proc Natl Acad Sci USA. 99:361–3620.
2002. View Article : Google Scholar
|
|
17
|
Mao X, Seidlitz E, Truant R, Hitt M and
Ghosh HP: Re-expression of TSLC1 in a non-small-cell lung cancer
cell line induces apoptosis and inhibits tumor growth. Oncogene.
23:5632–5642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang JY, Jiang SH, Liu DJ, Yang XM, Huo
YM, Li J, Hua R, Zhang ZG and Sun YW: Decreased LKB1 predicts poor
prognosis in pancreatic ductal adenocarcinoma. Sci Rep.
5:105752015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Nagata M, Sakurai-Yageta M, Yamada D, Goto
A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, et
al: Aberrations of a cell adhesion molecule CADM4 in renal clear
cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar
|
|
21
|
Liu Y, Zhang R, Yan K, Chen F, Huang W, Lv
B, Sun C, Xu L, Li F and Jiang X: Mesenchymal stem cells inhibit
lipopolysaccharide-induced inflammatory responses of BV2 microglial
cells through TSG-6. J Neuroinflammation. 11:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerber MA, Bahr SM and Gutmann DH: Protein
4.1B/differentially expressed in adenocarcinoma of the lung-1
functions as a growth suppressor in meningioma cells by activating
Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res.
66:5295–5303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rice TW, Rusch VW, Ishwaran H and
Blackstone EH: Cancer of the esophagus and esophagogastric
junction: Data-driven staging for the seventh edition of the
American Joint Committee on Cancer/International Union Against
Cancer Cancer Staging Manuals. Cancer. 116:3763–3773. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Kaabi A, van Bockel LW, Pothen AJ and
Willems SM: p16INK4A and p14A RF gene promoter hypermethylation as
prognostic biomarker in oral and oropharyngeal squamous cell
carcinoma: A review. Dis Markers. 2014:2605492014. View Article : Google Scholar
|
|
25
|
Baylin SB and Chen WY: Aberrant gene
silencing in tumor progression: Implications for control of cancer.
Cold Spring Harb Symp Quant Biol. 70:427–433. 2005. View Article : Google Scholar
|
|
26
|
Wong SY, Haack H, Kissil JL, Barry M,
Bronson RT, Shen SS, Whittaker CA, Crowley D and Hynes RO: Protein
4.1B suppresses prostate cancer progression and metastasis. Proc
Natl Acad Sci USA. 104:12784–12789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Xu R, Li G, Xie X, Long J and
Wang H: Loss of expression of the differentially expressed in
adenocarcinoma of the lung (DAL-1) protein is associated with
metastasis of non-small cell lung carcinoma cells. Tumour Biol.
33:1915–1925. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma X, Wang YW, Zhang MQ and Gazdar AF: DNA
methylation data analysis and its application to cancer research.
Epigenomics. 5:301–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kikuchi S, Yamada D, Fukami T, Masuda M,
Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y,
Onizuka M, et al: Promoter methylation of DAL-1/4.1B predicts poor
prognosis in non-small cell lung cancer. Clin Cancer Res.
11:2954–2961. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bock C, Halbritter F, Carmona FJ, Tierling
S, Datlinger P, Assenov Y, Berdasco M, Bergmann AK, Booher K,
Busato F, et al BLUEPRINT consortium: Quantitative comparison of
DNA methylation assays for biomarker development and clinical
applications. Nat Biotechnol. 34:726–737. 2016. View Article : Google Scholar
|
|
32
|
Reed K, Poulin ML, Yan L and Parissenti
AM: Comparison of bisulfite sequencing PCR with pyrosequencing for
measuring differences in DNA methylation. Anal Biochem. 397:96–106.
2010. View Article : Google Scholar
|
|
33
|
Hömig-Hölzel C and Savola S: Multiplex
ligation-dependent probe amplification (MLPA) in tumor diagnostics
and prognostics. Diagn Mol Pathol. 21:189–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuns R, Kissil JL, Newsham IF, Jacks T,
Gutmann DH and Sherman LS: Protein 4.1B expression is induced in
mammary epithelial cells during pregnancy and regulates their
proliferation. Oncogene. 24:6502–6515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deshpande A, Sicinski P and Hinds PW:
Cyclins and cdks in development and cancer: A perspective.
Oncogene. 24:2909–2915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y,
Li J, Zhang Y, Wang F, Chen N, Chen H, et al: Tivantinib induces
G2/M arrest and apoptosis by disrupting tubulin polymerization in
hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1182015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Castedo M, Perfettini JL, Roumier T,
Andreau K, Medema R and Kroemer G: Cell death by mitotic
catastrophe: A molecular definition. Oncogene. 23:2825–2837. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Löbrich M and Jeggo PA: The impact of a
negligent G2/M checkpoint on genomic instability and cancer
induction. Nat Rev Cancer. 7:861–869. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo M, Ren J, House MG, Qi Y, Brock MV and
Herman JG: Accumulation of promoter methylation suggests epigenetic
progression in squamous cell carcinoma of the esophagus. Clin
Cancer Res. 12:4515–4522. 2006. View Article : Google Scholar
|
|
40
|
Salam I, Hussain S, Mir MM, Dar NA,
Abdullah S, Siddiqi MA, Lone RA, Zargar SA, Sharma S, Hedau S, et
al: Aberrant promoter methylation and reduced expression of p16
gene in esophageal squamous cell carcinoma from Kashmir valley: A
high-risk area. Mol Cell Biochem. 332:51–58. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taghavi N, Biramijamal F, Sotoudeh M,
Khademi H, Malekzadeh R, Moaven O, Memar B, A'rabi A and
Abbaszadegan MR: p16INK4a hypermethylation and p53, p16 and MDM2
protein expression in esophageal squamous cell carcinoma. BMC
Cancer. 10:1382010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zare M, Jazii FR, Alivand MR, Nasseri NK,
Malekzadeh R and Yazdanbod M: Qualitative analysis of Adenomatous
Polyposis Coli promoter: Hypermethylation, engagement and effects
on survival of patients with esophageal cancer in a high risk
region of the world, a potential molecular marker. BMC Cancer.
9:242009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee EJ, Lee BB, Kim JW, Shim YM, Hoseok I,
Han J, Cho EY, Park J and Kim DH: Aberrant methylation of Fragile
Histidine Triad gene is associated with poor prognosis in early
stage esophageal squamous cell carcinoma. Eur J Cancer. 42:972–980.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo H, Zhou X, Lu Y, Xie L, Chen Q, Keller
ET, Liu Q, Zhou Q and Zhang J: Translational progress on tumor
biomarkers. Thorac Cancer. 6:665–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kaz AM and Grady WM: Epigenetic biomarkers
in esophageal cancer. Cancer Lett. 342:193–199. 2014. View Article : Google Scholar
|
|
46
|
Fareed KR, Kaye P, Soomro IN, Ilyas M,
Martin S, Parsons SL and Madhusudan S: Biomarkers of response to
therapy in oesophago-gastric cancer. Gut. 58:127–143. 2009.
View Article : Google Scholar
|
